Adult medulloblastoma in an Australian population

[1]  K. Aldape,et al.  The Alliance AMBUSH Trial: Rationale and Design , 2022, Cancers.

[2]  A. Brandes,et al.  Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment? , 2022, Cancers.

[3]  H. Arai,et al.  Bevacizumab, irinotecan, and temozolomide with re-irradiation in adult recurrent medulloblastoma: A first case report , 2021 .

[4]  M. Weller,et al.  Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 , 2021, Cancers.

[5]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[6]  K. Pajtler,et al.  How we treat medulloblastoma in adults , 2021, ESMO open.

[7]  D. Indelicato,et al.  Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes , 2021, Journal of Neuro-Oncology.

[8]  M. Martínez-García,et al.  SEOM clinical guideline for management of adult medulloblastoma (2020) , 2021, Clinical and Translational Oncology.

[9]  P. Wen,et al.  Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  M. Gilbert,et al.  Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  A. Silvani,et al.  Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology) , 2020, Neurological Sciences.

[12]  M. Weller,et al.  Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study , 2020, Journal of Neuro-Oncology.

[13]  A. Cervantes,et al.  Personalized Medicine: Recent Progress in Cancer Therapy , 2020, Cancers.

[14]  M. J. van den Bent,et al.  EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. , 2019, The Lancet. Oncology.

[15]  T. Gupta,et al.  Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping , 2019, Journal of Neuro-Oncology.

[16]  G. Noël,et al.  Medulloblastoma: optimizing care with a multidisciplinary approach , 2019, Journal of multidisciplinary healthcare.

[17]  David T. W. Jones,et al.  Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) , 2018, Neuro-oncology.

[18]  Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017 , 2018, Asia-Pacific journal of clinical oncology.

[19]  T. MacDonald,et al.  Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma , 2017, Neuro-oncology.

[20]  V. Ramaswamy,et al.  Medulloblastoma in adults: they're not just big kids. , 2016, Neuro-oncology.

[21]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[22]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[23]  Michael C. Rusch,et al.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Indelicato,et al.  Late toxicity following craniospinal radiation for early-stage medulloblastoma , 2014, Acta oncologica.

[25]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[26]  M. Rosenthal,et al.  Local perspective on a rare brain tumour: adult medulloblastoma , 2013, Internal medicine journal.

[27]  T. Pietsch,et al.  Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. , 2013, European journal of cancer.

[28]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[29]  S. Croul,et al.  Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Kavan,et al.  Characteristics and outcomes of medulloblastoma in adults , 2008, Pediatric blood & cancer.

[31]  J. Buckner,et al.  High‐dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system , 2008, Cancer.

[32]  R. Lai Survival of patients with adult medulloblastoma , 2008, Cancer.

[33]  P. Burger,et al.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Rorke,et al.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Souweidane,et al.  Long-term outcomes of adult medulloblastoma patients treated with radiotherapy , 2017, Journal of Neuro-Oncology.

[36]  M. Rosenblum,et al.  High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.